CSE: IZO
OTCQB: IZOZF
FSE: 1R3
Home
IzoView
Presentations
Fact Sheets
Media
IzoView Images
Podcast
Videos
News
FAQ
For Investors
For Clinicians
For Breast Cancer Advocates
Team
Management
Advisors
Investors
Why Invest?
Stock Info
Financials
Contact
Menu
News
2025
7/15/2025
Izotropic Prepares New Platforms to Educate and Engage
VIEW
6/13/2025
Izotropic Provides Marketing Update
VIEW
6/10/2025
Izotropic Updates License Agreement Terms with University of California
VIEW
5/16/2025
Izotropic’s U.S. FDA Regulatory Pathway Greenlit, Company Provides Corporate Update
VIEW
4/2/2025
Izotropic Engages International Communications Consultant, Grants Incentive Stock Options & RSUs to Key Personnel, Amends Promissory Note with Primary Lender
VIEW
3/25/2025
Izotropic Completes Pre-Submission Meeting with FDA for Breast Cancer Screening Indication
VIEW
3/10/2025
Izotropic to Present at Investor Conference March 13th
VIEW
2/19/2025
FDA Sets Meeting Date with Izotropic
VIEW
2/14/2025
Izotropic Closes Non-Brokered Private Placement
VIEW
2/7/2025
Izotropic Announces Non-Brokered Private Placement- February 2025
VIEW
1/29/2025
Izotropic Announces Timelines and Milestones to IzoView Product Launch
VIEW
1/17/2025
Izotropic Featured in Announcement of Research and Markets’ U.S. Breast Cancer Analysis and Forecast
VIEW
1/15/2025
Izotropic Announces Team Leading Clinical Study Design and FDA Regulatory Submissions
VIEW
1/9/2025
Izotropic Files Pre-Submission with U.S. FDA for Breast Cancer Screening
VIEW
IzoView
Presentations
Fact Sheets
Media
IzoView Images
Podcast
Videos
News
FAQ
For Investors
For Clinicians
For Breast Cancer Advocates
Team
Management
Advisors
Investors
Why Invest?
Stock Info
Financials
Contact